beta
Trial Radar IA
Lo studio clinico NCT05730569 (DenBalo) per Nascita pretermine, Basso peso alla nascita, Piccolo per età gestazionale alla nascita è in arruolamento. Consulti la vista a schede del Radar degli Studi Clinici e gli strumenti di scoperta IA per tutti i dettagli. Oppure, ponga pure una domanda qui.
Un studio corrisponde ai criteri del filtro
Vista a schede

Description and Comparison of Biological Vulnerability in Small Vulnerable Newborns Versus Healthy Community Controls in Urban Burkina Faso (DenBalo)

In arruolamento
I dettagli dello studio clinico sono disponibili principalmente in inglese. Tuttavia, Trial Radar IA può essere d'aiuto! Basta cliccare su 'Spiega lo studio' per visualizzare e discutere le informazioni sullo studio nella lingua selezionata.
La sperimentazione clinica NCT05730569 (DenBalo) è uno studio osservazionale per Nascita pretermine, Basso peso alla nascita, Piccolo per età gestazionale alla nascita, attualmente in arruolamento. Avviato il 9 gennaio 2023, prevede di arruolare 140 partecipanti. Sotto la guida di l'Università di Gand, dovrebbe concludersi entro il 31 luglio 2024. I dati più recenti da ClinicalTrials.gov sono stati aggiornati l'ultima volta il 31 maggio 2024.
Sommario breve

The aim of the DenBalo study is to apply integrated multi-omics methods to examine the biological mechanisms underlying this vulnerability in Small Vulnerable Newborns (SVNs) in LMICs, with the ultimate goal of identifying targeted interventions to reduce morbidity and mortality in this high-risk population. The evidence generated from this project will ultimately help promote healthy pregnancies and the birth of healthy babies.

To achieve this goal, three research objectives are proposed:

  1. To describe and compare gut microbiota, immune system and breastmilk components in SVNs versus healthy community controls in urban Burkina Faso.
  2. To describe and compare the development of the gut microbiota, the immune system and breastmilk components during the first six months of life in SVNs versus healthy community controls in urban Burkina Faso.
  3. To investigate the relationship between the composition of the gut microbiota, the immune system and breastmilk components during the first six months of life in SVNs versus healthy community controls in urban Burkina Faso.
Descrizione dettagliata
The first days and weeks of life are characterized by a truly impressive cascade of biological processes that drive neonatal growth and development-all of which are crucial to preparing the newborn for life outside the womb.

First, vaginal delivery exposes neonates to an important natural microbial inoculum from the vaginal microbiota in labor and from the maternal intestinal microbiota at birth. Together, these early colonization events lay the foundation for gut microbiota assembly, inform the arrival of subsequent species through microbial interactions, and dictate infant microbiota maturation. A recent study has shown that a handful of bacteria begin colonizing the infant gut within the first days of life, that gut microbes accumulate gradually over time, and that pioneer strains are retained after a month of life. Whether the gut microbial assembly, maturation, and functional potential differs between SVNs versus healthy, community controls, or is coupled to growth and development, remains unresolved.

Secondly, the first days and weeks of life represent a time of heightened vulnerability to infectious disease. Neonatal infections account for a tragic 40% of mortality in children under five years of age. This critical time period is increasingly seen as a key determinant in health over the entire lifespan. A recent study using a high-dimensional, unbiased approach to characterize neonatal immune system development reported a dramatic, purposeful trajectory in the first week of life. While much remains to be explored, what is known is that early microbial colonization is vital to optimal host immune development and protection from disease and that, after birth, the most important determinant of infant gut colonization is breastfeeding. The impacts of preterm birth, low birth weight, or small for gestational age on immune development and function remain enigmatic and the mediating effect of the gut microbiome unknown.

Thirdly, neonatal nutrition plays a vital role in the two aforementioned processes-because breastfeeding both initiates tropic priming of the newborn gut and transfers numerous immunological factors to the baby. However, few studies have explored the synergy between neonatal microbiome and immunome development, and even fewer through the lens of newborn nutrition. Moreover, virtually zero studies include an integrated characterization of these processes in the SVN. Evidence suggests that, compared to mothers of full-term neonates, the colostrum from mothers of preterm newborns has higher protein and fat content, free amino acids, sodium, and bioactive milk components including HMOs, cytokines, and lactoferrin. But because few studies have evaluated the association between early milk composition and infant growth and development, it is unclear which components are most imperative for a healthy gut microbiota and a robust immune system, particularly in the SVN.

Major advances in systems biology approaches allowing for unbiased, integrated analyses of high-dimensional -omic databases have provided the critical bioinformatic toolkit required to address these questions. Indeed, the ground has never been more fertile for a step-change in commitment to high-impact research on neonatal microbiome and immunome development and the synergy with newborn nutrition.

Titolo ufficiale

Description and Comparison of Biological Vulnerability in Small Vulnerable Newborns Versus Healthy Community Controls in Urban Burkina Faso (DenBalo): Gut Microbiota, Immune System, and Breastmilk Assembly and Development in the First Days and Weeks of Life

Condizioni
Nascita pretermineBasso peso alla nascitaPiccolo per età gestazionale alla nascita
Pubblicazioni
Articoli scientifici e documenti di ricerca pubblicati su questo studio clinico:
Altri ID dello studio
  • DenBalo
  • ONZ-2022-0500
  • INV-035474 & INV-036154 (Altro numero di finanziamento) (Bill & Melinda Gates Foundation)
  • 050-2022/CEIRES (Altro identificativo) (Comité d'Éthique Institutionnel pour la Recherche en Sciences de la Santé)
Numero NCT
Data di inizio (effettiva)
2023-01-09
Ultimo aggiornamento pubblicato
2024-05-31
Data di completamento (stimata)
2024-07-31
Arruolamento (previsto)
140
Tipo di studio
Osservazionale
Stato
In arruolamento
Parole chiave
Preterm Birth
Low Birth Weight
Small for Gestational Age
Small Vulnerable Newborn
Bracci / Interventi
Gruppo/Braccio di partecipantiIntervento/Trattamento
Small Vulnerable Newborns
* Low birth weight: \<2500g; and/or, * Preterm: born between the 34th and 37th week of pregnancy; and/or, * Small for Gestational Age: \<10 percentile of INTERGROWTH-21st birthweight standards.
N.D.
Healthy Community Controls
* Born after the 37th week of pregnancy; and, * Birth weight ≥2500g; and, * ≥10 percentile of INTERGROWTH-21st birthweight standards.
N.D.
Esito primario
Misure di esitoDescrizione della misuraArco temporale
Differential abundances of bacterial genera in the infant gut microbiota
Shotgun metagenomic sequencing
to be assessed at on days 3, 7, 14, 30, 60, 180 of life
Esito secondario
Misure di esitoDescrizione della misuraArco temporale
Infant gut microbiota α and β diversity
Shotgun metagenomic sequencing
to be assessed at on days 3, 7, 14, 30, 60, 180 of life
Infant plasma immunophenotyping
Flow cytometry
to be assessed at birth and on days 1, 3, 5, 7, 30, 60 of life
Infant plasma chemokine and cytokine analyses
Electrochemiluminescence and the MSD V-PLEX Human Biomarker 54-Plex Kit
to be assessed at birth and on days 1, 3, 5, 7, 30, 60 of life
Maternal breastmilk component* profiling
\*Components include macronutrients, micronutrients, oligosaccharides, growth factors, immunoglobulins, cytokines, metabolites, microbes, and proteins.
on days 3, 7, 14, 30, 60 of life
Criteri di eleggibilità

Età idonea
Bambino, Adulto, Adulto anziano
Età minima
15 Years
Sessi idonei
Tutti
Accetta volontari sani
  • Fundal height between 24 and 27 cm
  • Woman living in the health zone of Accart-Ville, Colma 1 or Farakan
  • Woman not planning to give birth or move outside the study area in the first 6 months of the infant's life
  • Gestational age between 24 weeks 0 completed day and 29 weeks 6 days (ultrasound)
  • Monofetal pregnancy without visible malformation
  • Woman agreeing to give her informed consent to participate in the study
  • Delivery of a live birth
  • Vaginal birth
  • Absence of severe infectious pathology, severe pneumopathy or respiratory distress in the neonate
  • Neonates who did not receive corticosteroids or antibiotics at birth

For Small Vulnerable Newborns (SVNs):

  • Low birth weight: <2500g; and/or,
  • Preterm: born between the 34th and 37th week of pregnancy; and/or,
  • Small for Gestational Age: <10 percentile of INTERGROWTH-21st birthweight standards.

For healthy community controls:

  • Neonate born after the 37th week of pregnancy; and,
  • Birth weight >2500g; and,
  • ≥10 percentile of INTERGROWTH-21st birthweight standards; and,
  • Possible match with a SVN neonate already recruited into the study.

  • Fundal height <24 cm or >27 cm
  • Woman living outside the sanitary zone of the Accart-Ville, Colma 1 or Farakan
  • Woman planning to give birth outside the study area or to move from it within the first 6 months of the infants's life
  • Gestational age <24 weeks or ≥30 weeks (ultrasound)
  • Multi-fetal pregnancy
  • Malformation visible on ultrasound
  • Cesarean delivery
  • Neonate with severe infectious disease, severe pneumopathy or respiratory distress
  • Neonate who received corticosteroids or antibiotics just after birth
Contatti principali dello studio
Contatto: Trenton Dailey-Chwalibóg, MPH, PhD, +33603233614, [email protected]
1 Centri dello studio in 1 paesi
Agence de Formation, de Recherche et d'Expertise en Santé pour l'Afrique (AFRICSanté), Bobo-Dioulasso, Burkina Faso
Moctar Ouédraogo, MS, Contatto, +22670238198, [email protected]
Laeticia C Toé, MD, MS, Investigatore principale
Lionel O Ouédraogo, MD, MS, Sub-investigatore
Cheick A Ouattara, MD, MS, PhD, Sub-investigatore
Moctar Ouédraogo, MS, Sub-investigatore
In arruolamento